RiboBio, GE Healthcare Partner for Oligonucleotide Drug Development

RiboBio Co., Ltd. and GE Healthcare Life Sciences held a strategic partnership signing ceremony at the 5th Canton Nucleic Acids Forum in Guangzhou, China. 

Dr. Biliang  Zhang, president of RiboBio, and Mrs. Shufang Lim, chief commercial director of GE Healthcare Life Science China, executed the strategic partnership. The agreement aims to jointly build Asia’s largest oligonucleotide drug development and manufacturing facility, and also to provide a total solution for oligonucleotide drug companies worldwide.

Under the terms of the agreement, GE Healthcare will provide the advanced instrumentation, including its new IN Cell Analyzer 6500HS and Äkta OligoProcess systems, while RiboBio will provide new, state-of-the-art facilities, highly trained scientific staff, and support infrastructure with the goal to build Asia’s leading oligonucleotide drug contract research organization and Asia’s largest contract oligonucleotide manufacturing operation.